PubMed Health⌕ Search

PubMed · 10483248

[Painless (silent) thyroiditis].

Abstract

Silent thyroiditis (ST) is the second major cause of thyrotoxicosis, following Graves' disease (GD) in Japan. Thyrotoxicosis develops differently in these two disorders: GD stimulates TSH receptors through antibody binding, while ST destroys follicles, probably through an autoimmune mechanism. Distinguishing between ST and GD depends mainly on serum TSH receptor antibody titer and radioactive iodine uptake. In our long-term observation of ST patients, ST recurred with a high incidence (65%, 35/54). Some ST patients developed GD later, and ST developed in patients with a history of GD. Thus, the differential diagnosis between these two diseases is very important, even when a patient has a history of either ST or GD. A simpler diagnostic test specific to ST would be of great use.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Y Ozawa. 1999. [Painless (silent) thyroiditis].. https://pubmed.ncbi.nlm.nih.gov/10483248/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Orbital radiotherapy for Graves' ophthalmopathy: useful or useless? Safe or dangerous?

Treatment of Graves' ophthalmopathy does not always provide favorable results. After several decades of efforts, glucocorticoids, orbital radiotherapy (OR) and surgery (orbital decompression) remain the milestones in the management of this disease. OR produce favorable results in about 55-60% of patients. Its effectiveness is increased by the association with systemic glucocorticoids. Recent studies have cast some doubts on its real effectiveness and this is discussed by participants in this Forum. Selection of patients is particularly important to assess treatment outcome, because OR is unlikely to provide beneficial effects in patients with longstanding and inactive eye disease. OR is a safe procedure, with very limited side-effects. It should be used in patients older than 35 years of age. It is recommended that a large, multi-center, prospective, randomized and controlled study with well defined inclusion criteria be carried out to draw sound conclusions on the role of OR in the management of Graves' ophthalmopathy.

Graves Disease↗